Company Encyclopedia
View More
name
Benitec Biopharma
BNTC.US
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene for the treatment of oculopharyngeal muscular dystrophy related dysphagia. Benitec Biopharma Inc.
1.946 T
BNTC.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Benitec Biopharma Inc. held annual stockholder meeting

    Benitec Biopharma Inc. held its 2025 Annual Meeting of Stockholders on December 1, 2025. Stockholders elected Dr. Jerel Banks and Megan Boston to the board of directors, ratified the appointment of the independent registered public accounting firm, and approved all proposals presented at the meeting.

    Reuters·
    US
    BNTC
    +4.77%
    Reuters·
    US
    BNTC
    +4.77%

    Benitec Biopharma Reports Increased Quarterly Loss Amid Rising Expenses

    Benitec Biopharma reported a Q1 net loss of $8.965 million, up from $5.059 million the previous year, due to increased operating expenses of $9.803 million. Despite the losses, the company holds $94.5 million in cash and remains focused on advancing clinical trials and exploring collaborations.

    Tip Ranks·
    US
    BNTC
    +4.77%
    Tip Ranks·
    US
    BNTC
    +4.77%

    Benitec Biopharma Releases First Quarter 2026 Financial Results and Provides Operational Update

    -Fast Track Designation was granted for BB-301 following U.S. Food and Drug Administration ( FDA ) review of positive interim clinical study results and proprietary Responder Analysis planned for use in pivotal study for ...

    GlobeNewswire·
    US
    BNTC
    +4.77%
    GlobeNewswire·
    US
    BNTC
    +4.77%

    Benitec Biopharma | 8-K: FY2026 Q1 Revenue: USD 0

    LB filings·
    US
    BNTC
    +4.77%
    LB filings·
    US
    BNTC
    +4.77%

    Benitec Biopharma reports first quarter net loss of $9.0 million

    Benitec Biopharma Inc. reported a net loss of $9.0 million for the quarter ended September 30, 2025, with no revenues, and increased operating expenses of $9.8 million. General and administrative costs rose significantly, while R&D expenses slightly decreased. The company raised $100 million through a public stock offering and received FDA Fast Track Designation for its BB-301 candidate. Cash reserves were $94.5 million as of September 30, 2025.

    Reuters·
    US
    BNTC
    +4.77%
    Reuters·
    US
    BNTC
    +4.77%
    © 2025 Longbridge｜Disclaimer